Kazia to team up with U.S. oncology group for brain cancer drug trial
Category: #health  By Mateen Dalal  Date: 2019-05-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Kazia to team up with U.S. oncology group for brain cancer drug trial

A multi-centre phase-two study will represent the fourth clinical trial ongoing for Kazia’s GDC-0084 drug candidate

Kazia Therapeutics Ltd, an Australian oncology-focused biotechnology company, has recently entered into a partnership with the Alliance for Clinical Trials in Oncology Foundation, the US-based cancer research network, for introducing a multi-centre phase-two study exploring the potential use of GDC-0084 drug from Kazia in treating brain metastases.

Apparently, a multi-centre phase-two study will represent the fourth clinical trial ongoing for Kazia’s GDC-0084 drug candidate, with every trial treating different types of brain cancer. Alliance for Clinical Trials in Oncology Foundation is sponsored by the National Cancer Institute and it will examine various other targeted cancer therapies.

James Garner, Chief Executive Officer of Kazia, stated that patients will be assigned to treatment based on their individual genetic signature of tumour and apart from this, patients with a mutation that affects the PI3K pathway will be entitled to get GDC-0084.

Seemingly, Alliance would be initiating the open-label phase-two study which will aid in allocating to patients either entrectinib (Genentech), abemaciclib (Eli Lilly) or Kazia’s GDC-0084 drug, based on their tumour’s genetic profile.

Sources familiar with the matter mentioned that the trial is projected to recruit nearly 150 patients across various US medical centres and Kazia will provide support, including a financial grant and the study drug. With regards to the PI3K pathway, only patients with a genetic alteration will get GDC-0084 drug, which is anticipated to include around one-third of total patients employed.

On the other hand, patients with other kind of genetic mutations will get either Trk/ALK inhibitor entrectinib which is still in process of approval by the Federal Drug Administration (FDA), or CDK inhibitor abemaciclib, approved by the FDA for the treatment of certain types of breast cancer.

The study is reportedly expected to take around two years to complete and will be organized under an investigator IND along with the US FDA, where Alliance will undertake key regulatory responsibilities for the study.

 

Source credit: https://www.proactiveinvestors.com.au/companies/news/220551/kazia-therapeutics-to-collaborate-with-us-based-oncology-foundation-on-clinical-trials-for-metastatic-brain-cancer-treatment-220551.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Hyundai plans to raise stake in China’s Sichuan Hyundai Motor
Hyundai plans to raise stake in China’s Sichuan Hyundai Motor
By Mateen Dalal

Hyundai Motor Company identifies the significance and impact of automobiles, and strives to fulfill its goals by creating new and advanced vehicles that addresses all the vital issues faced by drivers. The automobile giant has effectively become...

TransPerfect expands its portfolio by acquiring Sublime Subtitling
TransPerfect expands its portfolio by acquiring Sublime Subtitling
By Mateen Dalal

With decades of hard work and hands-on experience, TransPerfect has managed to become one of the largest global providers of technology and language solutions for companies worldwide. With over 5,000 global organizations employing its GlobalLink®...

Altran to launch a Digital Therapeutics Innovation Center in Boston
Altran to launch a Digital Therapeutics Innovation Center in Boston
By Mateen Dalal

Digital therapeutics are evidence-based interventions conducted by advanced software programs to manage, treat or prevent clinical disorders. Its adoption has augmented the whole medical industry, making it simpler for practitioner to ...